Date: 2018-05-30
Type of information: Nomination
Compound: board of directors
Company: Allogene Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 30, 2018, Allogene Therapeutics announced the company’s board of directors. Allogene was launched in April 2018 with one of the largest Series A financings in
biotechnology of $300 million from a premier investment consortium that includes Two River, TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief
Investment Officer, Gilead and Pfizer. The Allogene Board of Directors:
- • Arie Belldegrun, Executive Chairman and Co-Founder of Allogene
- • David Bonderman – Chairman and Founding Partner of TPG
- • David Chang, President, Chief Executive Officer and Co-Founder of Allogene
• Franz B. Humer, Former Chairman and CEO of Roche
• John DeYoung, Vice President, Worldwide Business Development at Pfizer
• Joshua Kazam, Co-Founder and Partner of Two River and Co-Founder of Allogene
• Owen Witte, University Professor of Microbiology, Immunology and Molecular Genetics at the UCLA, David Saxon Presidential Chair in Developmental Immunology;
and Director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA
• Robert Abraham, Senior Vice President and Group Head, Oncology R&D Group at Pfizer
• Todd Sisitsky – Managing Partner of TPG Capital
Financial terms:
Latest news:
Is general: Yes
